Phase 2 Study of the Efficacy and Safety of Erdafitinib in Patients With Bacillus Calmette-Guérin (BCG)-Unresponsive, High-Risk Non–Muscle-Invasive Bladder Cancer (HR-NMIBC) With FGFR3/2 Alterations (alt) in THOR-2: Cohort 2 Interim Analysis Results

Catto, James W.F., Tran, Ben, Master, Viraj A., Roupret, Morgan, Pignot, Geraldine, Tubaro, Andrea, Shimizu, Nobuaki, Vasdev, Nikhil, Gschwend, Juergen, Loriot, Yohann, Nishiyama, Hiyoyuki, Redorta, Joan, Daneshmand, Siamak, Miura, Yuji, Naini, Vahid, Crow, Lauren, Triantos, Spyros, Baig, Mahadi and Steinberg, Gary D. (2023) Phase 2 Study of the Efficacy and Safety of Erdafitinib in Patients With Bacillus Calmette-Guérin (BCG)-Unresponsive, High-Risk Non–Muscle-Invasive Bladder Cancer (HR-NMIBC) With FGFR3/2 Alterations (alt) in THOR-2: Cohort 2 Interim Analysis Results. In: ASCO Genitourinary Cancers Symposium, 2023-02-16 - 2023-02-18, 2023 Moscone West • San Francisco, CA.
Copy

Patients presenting with NMIBC carcinoma in situ (CIS) have a high risk of progression1,2FGFR inhibition may benefit patients with CIS with FGFRalt who are unresponsive to fi rst-line BCG, for whom treatment options, other than radical cystectomy, are limited3-5– Data are limited in patients with CIS only, but in the broader NMIBC population the prevalence of FGFR3alt is up to 80%6Erdafi tinib, an oral selective pan-FGFR tyrosine kinase inhibitor, is approved for locally advanced or metastatic urothelial cancer in adults with susceptible FGFR3/2alt who have progressed during or after ≥1 line of platinum-containing chemotherapy7-9 THOR-2 (NCT04172675) is a multicohort phase 2 study of erdafi tinib in patients with HR-NMIBC.


picture_as_pdf
ASCO_GU_poster_Cohort_2_25Jan23_STA.pdf
subject
Submitted Version

View Download

Atom BibTeX OpenURL ContextObject in Span OpenURL ContextObject Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation METS MODS RIOXX2 XML Reference Manager Refer ASCII Citation
Export

Downloads